Head-to-head evidence
SYR-472 vs Teneligliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
SYR-472
Developed by Takeda Pharmaceutical Company
NCT02324569 · Phase 3 · completed
The 12-week comparison randomized 240 participants and used quadruple blinding with placebo control. The primary HbA1c endpoint was met, with a statistically significant treatment difference, but HbA1c is a surrogate laboratory measure rather than a hard clinical endpoint; the subsequent long-term period was open-label.
Teneligliptin · Tenelia
Developed by Mitsubishi Tanabe Pharma
NCT00974090 · Phase 3 · completed
The trial was properly randomized and double-blinded with a placebo control and a real hard clinical endpoint (HbA1c change), and enrollment (~96-98 per arm) was reasonable for a 12-week phase 3 add-on study. However, the posted results report only least-squares mean changes with standard errors and no explicit statistical significance test for the primary comparison, so while the numeric difference favors teneligliptin, whether it formally met its pre-specified endpoint cannot be confirmed from this record alone.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SYR-472's landscape · Teneligliptin's landscape